BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Disposal
Focus on B2B-business
Monteil Cosmetics International GmbH, based in Düsseldorf, is represented as a brand company in the cosmetics end customer business (B2C). It has been part of the BRAIN Group since 2011. Most recently, BRAIN AG held 68.3% of the Monteil shares, while Wilde Cosmetics GmbH acted as a minority shareholder. The sale of the loss-making investment will unburden the BRAIN Group both financially and in terms of capacity and allow it to concentrate fully on the further expansion of the product-scalable B2B business.
"The focus of the BRAIN Group is on growing the product business with industrial partners. The companies in the BRAIN Group are now fully specialized in R&D and B2B business. This is where we see the absolute strengths of the BRAIN Group, which we are continuously expanding", says Dr. Jürgen Eck, CEO of BRAIN AG.
"We have taken a further step towards consistently implementing our strategy. The pure B2B cosmetics business is and will remain part of the growth strategy", says Ludger Roedder, CBO of BRAIN AG.
"The sale of the Monteil shares has no impact on the forecasts of BRAIN AG for the current 2018/19 financial year. Rather, we confirm the objective of achieving a double-digit growth rate in total operating performance and improved EBITDA at Group level", adds Manfred Bender, CFO of BRAIN AG.
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.de/en.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
|Company:||B.R.A.I.N. Biotechnology Research And Information Network AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||830387|
|End of News||DGAP News Service|